Quarterly Result28 May 2026, 10:37 pm
SPML FY26 Profit up to ₹13.03 Cr; Board Approves Audited Results
AI Summary
Speciality Medicines Limited (SPML) announced the outcome of its Board Meeting held on May 28, 2026. The Board approved and took on record the Audited Standalone Financial Statements and Results for the half-year and financial year ended March 31, 2026, along with the Auditor's Report, which had an unmodified opinion. For the financial year ended March 31, 2026, the company reported Revenue from Operations of ₹7,528.51 Lakh and a Profit for the period of ₹1,303.29 Lakh. The Board also noted the utilization of Initial Public Issue (IPO) proceeds for the same period, confirming adherence to the objects stated in the prospectus.
Key Highlights
- Board approved audited standalone financial results for FY26.
- FY26 Revenue from Operations reached ₹7,528.51 Lakh.
- FY26 Profit for the period stood at ₹1,303.29 Lakh.
- Auditor's report for FY26 financial results received an unmodified opinion.
- Utilization of IPO proceeds for FY26 was noted and confirmed as per prospectus.
Price Impact
More from SPML